Issue link: https://www.e-digitaleditions.com/i/1543258
Inhalation February 2026 7 https://www.e-digitaleditions. com/i/1540437-inh1025/25? Materials Compatibility Consid- erations for the Transition to Low Global Warming Potential Pro- pellants for Pressurized Metered Dose Inhalers. AAPS PharmSci- Tech, Volume 26, article num- ber 65, (2025). https://link. springer.com/article/10.1208/ s12249-025-03060-4. Get involved Visit the IPAC-RS website and follow IPAC-RS on LinkedIn for regular updates and to learn more. If your company is developing or considering small-molecule or biological products for deliv- ery to the respiratory tract, please contact us, and consider joining IPAC-RS to learn from your peers, stay abreast of regulatory and sci- entific developments, establish best practices and help shape the future of this field. For further information, contact marykate. bielinski@faegredrinker.com. of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline on Extractables and Leachables (ICH Q3E) and Supplementary Materials. Publications IPAC-RS output in 2025 included the following publications: Let's Dig Deeper: An Interview with the Authors of Point of View: A Better Way to Set Specifications and Control Quality—General Con- cepts and Examples. Inhalation, October 2025, Volume 19(5), pages 10-13, https://www.e-digitaledi tions.com/i/1540437-inh1025/11? Inhalable and Nasal Biolog- ics: Analytical, Formulation, Development, and Regulatory Considerations. Journal of Aero- sol Medicine and Pulmonary Drug Delivery, Volume 38 (5), https://www.liebertpub.com/doi/ abs/10.1089/jamp.2024.0058 Excipients to Consider in Devel- opment of Intranasal Pediatric Products. Inhalation, October 2025, Volume 19(5): pages 25-35, In 2025, IPAC-RS also held its 4th Sustainability Roundta- ble, "Designing for a Sustainable Future: Strategies to Address the Device and Delivery System Life- cyle" with a recording now avail- able at Roundtables | IPAC-RS. Regulatory activities IPAC-RS responded to the Request for Information (RFI) from the US Department of Health and Human Services (HHS), which invited public input on US regulations and guidance that should be revised, withdrawn or repealed ("10-to-1 Deregulation"). Among key topics raised by IPAC-RS were the need for better inter-center alignment at the FDA, and a more streamlined and clearer regulatory approach for pMDIs with new propellants. In collaboration with IPAC (its sister consortium), IPAC-RS sub- mitted joint comments on the Health Canada proposed PFAS Risk Management Approach. In addition, IPAC-RS prepared comments on the draft Interna- tional Council for Harmonisation